Zobrazeno 1 - 10 of 114 pro vyhledávání: '"J D Bitran"'
1
The Impact on Survival by Adjuvant Chemotherapy and Radiation Therapy in Stage II Non-Small-Cell Lung Cancer
Autor: William J Gradishar, S. Krishnasamy, R. Mick, J. D. Bitran, Harvey M. Golomb, Philip C. Hoffman, Mark K. Ferguson
Publikováno v: American Journal of Clinical Oncology. 15:405-411
Forty-nine consecutive patients with pathologic Stage II non-small-cell lung cancer treated over a 15-year period were retrospectively reviewed. The treatment strategy evolved during the period of review. Early patients were treated with surgery alon
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e3998ec96bcf9aaae660bcdf505a08
https://doi.org/10.1097/00000421-199210000-00004
Zobrazit plný text záznamu
2
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer
Autor: R P, Gale, R E, Park, R, Dubois, J D, Bitran, A, Buzdar, G, Hortobagyi, S E, Jones, G S, Lazar, G, Spitzer, S M, Swain, C B, Vaughn, C E, Vogel, S, Martino
Publikováno v: Clinical transplantation. 14(1)
There is controversy whether high-dose chemotherapy and a blood cell or bone marrow autotransplant is a better treatment than conventional-dose chemotherapy for women with local/regional or metastatic breast cancer. Subject selection and time-to-trea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::12e86c33199935e5f01dc848b67a3b72
https://pubmed.ncbi.nlm.nih.gov/10693633
Zobrazit plný text záznamu
4
Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy
Autor: J D, Bitran, B, Samuels, Y, Trujillo, L, Klein, L, Schroeder, J, Martinec
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 2(9)
Twenty-five patients with high-risk stage II and IIIA breast cancer (10 or more involved lymph nodes) were treated with six cycles of standard-dose chemotherapy (5-fluorouracil, doxorubicin, and cyclophosphamide) followed by high-dose chemotherapy (2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8ba34ce3dd3546a3dbf7bc1dc95e72ce
https://pubmed.ncbi.nlm.nih.gov/9816327
Zobrazit plný text záznamu
5
Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer
Autor: J D, Bitran, B, Samuels, L, Klein, S, Hanauer, L, Johnson, J, Martinec, E, Harris, J, Kempler, W, White
Publikováno v: Bone marrow transplantation. 17(2)
The aim of this phase II study was to determine the feasibility of using two (tandem) courses of high-dose alkylating agents with bone marrow or peripheral blood progenitor cell support in women with stage IV breast cancer. Women with stage IV breast
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e3fcd4e3da103aa12f421b78b8fd9f99
https://pubmed.ncbi.nlm.nih.gov/8640160
Zobrazit plný text záznamu
8
A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer
Autor: G A, Masters, L C, Drinkard, P C, Hoffman, N, Lane, S, Watson, B L, Samuels, J D, Bitran, H M, Golomb, E E, Vokes
Publikováno v: The cancer journal from Scientific American. 1(4)
The combination of cisplatin, 5-fluorouracil, and leucovorin (PFL) has been reported to have a 29% response rate in advanced non-small cell lung cancer. Vinorelbine, a semi-synthetic vinca alkaloid, has also been reported to have single-agent activit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2e18808b681831d7ca64784c4c5cf940
https://pubmed.ncbi.nlm.nih.gov/9166490
Zobrazit plný text záznamu
9
Cost-effectiveness analysis: sleeping with an enemy or a friend?
Autor: S C Gulati, J D Bitran
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13(9)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4579622d8edf1b9147a32992bcd161
https://pubmed.ncbi.nlm.nih.gov/8622010
Zobrazit plný text záznamu
10
Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer
Autor: P C, Hoffman, S A, Krauss, L C, Drinkard, G A, Masters, B L, Samuels, J D, Bitran, H M, Golomb, S, Watson, E E, Vokes
Publikováno v: Seminars in oncology. 22(4 Suppl 9)
Both paclitaxel and ifosfamide have significant single-agent activity in non-small cell lung cancer. We designed a phase I study combining escalating doses of paclitaxel, administered by 24-hour infusion, with ifosfamide given at a dose of 1.6 g/m2 d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::844f1587a4dbe7f26027b1f1594da63e
https://pubmed.ncbi.nlm.nih.gov/7544026
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje